Incidence of New or Worsening Overactive Bladder Among Patients with a Prior SARS-CoV-2 Infection: A Cohort Study.
European Urology Open Science
BACKGROUND: Literature is sparse on COVID-19-associated cystitis (CAC), a novel condition comprising frequency, urgency, and nocturia after COVID-19 infection.
OBJECTIVE: To determine the incidence of CAC and correlation with SARS-CoV-2 antibody levels.
DESIGN SETTING AND PARTICIPANTS: This was a retrospective study in which urinary symptoms were scored using the International Consultation on Incontinence Questionnaire-overactive bladder (ICIQ-OAB) at three time points: before the pandemic (January 2020), 2 mo after COVID-19 infection (if applicable), and at the time of the study (May 2021). The setting was a regional health care system. The 18 785 healthcare employees who took part in the BLAST COVID study group were invited to participate, of whom 1895 responded.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome measured was the percentage of COVID-positive patients with a significant change on ICIQ-OAB over time. Pearson's χ
RESULTS AND LIMITATIONS: Of the 1895 participants, 31.9% (
CONCLUSIONS: COVID-19 infection increases the risk of developing new or worsening OAB symptoms.
PATIENT SUMMARY: We compared overactive bladder symptoms in a large group of participants between individuals with and without a previous COVID-19 infection. We found that symptomatic infection was associated with a three times greater risk of developing new or worsening overactive bladder symptoms among COVID-19 patients.
Roberts LH, Zwaans BMM, Peters KM, Chancellor M, Padmanabhan P. Incidence of new or worsening overactive bladder among patients with a prior SARS-COV-2 infection: a cohort study. Eur Urol Open Sci. 2022 Dec;46:68-74. doi: 10.1016/j.euros.2022.10.001. PMID: 36245790.